Associated Papers
Prevalence and clinical relavance of germline mutations in Chinese patients with pancreatic cancer.
Jiang Y et al.
Cell Communication and Signaling : Ccs, 2025
The Cytochrome P450 2C8*3 Variant (rs11572080) Is Associated with Improved Asthma Symptom Control in Children and Altered Lipid Mediator Production and Inflammatory Response in Human Bronchial Epithelial Cells.
Almestica-Roberts M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences.
Camara MD et al.
Human Genomics, 2024
Genomic analyses of 10,376 individuals in the Westlake BioBank for Chinese (WBBC) pilot project.
Cong PK et al.
Nature Communications, 2022
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.
Iannaccone T et al.
Pharmaceuticals (basel, Switzerland), 2021
The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.
Milovanovic DD et al.
Balkan Journal of Medical Genetics : Bjmg, 2016
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Backman JT et al.
Pharmacological Reviews, 2016
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Lee SY et al.
European Journal of Cancer (oxford, England : 1990), 2014
Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.
Umamaheswaran G et al.
The Indian Journal of Medical Research, 2014
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.
Arnaldo P et al.
The Malaysian Journal of Medical Sciences : Mjms, 2013
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2013
Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
Hanioka N et al.
Basic & Clinical Pharmacology & Toxicology, 2010
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
Daily EB et al.
Pharmacogenomics, 2009
CYP450 pharmacogenetics for personalizing cancer therapy.
van Schaik RH
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2008
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.
Saito Y et al.
Pharmacogenetics and Genomics, 2007
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Deeken JF et al.
Anti-cancer Drugs, 2007
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
Nakajima Y et al.
Clinical Pharmacology and Therapeutics, 2006
Pharmacogenomics of cholesterol-lowering therapy.
Schmitz G et al.
Vascular Pharmacology, 2006
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
van Schaik RH
Investigational New Drugs, 2005
Statin response and pharmacokinetics variants.
Kajinami K et al.
Expert Opinion on Pharmacotherapy, 2005
Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.
Hichiya H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.
Ishikawa C et al.
Journal of Human Genetics, 2004